Nicotine Psychopharmacology pp 511-534

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 192)

Nicotine Psychopharmacology: Policy and Regulatory

  • Jack E. Henningfield
  • Mitch Zeller

Abstract

Powerful nerve agent, poison, addictive drug, or wonder medicine of the future? Nicotine has had a long and storied history in pharmacology, physiology, public health and, more recently, in regulatory policy initiatives in the United States and internationally. Psychopharmacology research on nicotine and tobacco came to particular prominence in the latter third of the twentieth century with exploration addressing the role of nicotine in tobacco use, the potential categorization of nicotine as an addictive drug, the pharmacological basis for treatment of tobacco addiction, and the perspective of policy developers seeking to reduce the toll of tobacco use. In fact, the 2005 ratification of the World Health Organization's first global health treaty, the Framework Convention on Tobacco Control, provides further impetus for extending the science foundation for tobacco disease control and policy efforts. Implementation of the treaty's provisions will control tobacco use and reduce the 500 million premature deaths projected to occur in the first half of the twenty-first century from tobacco use. Psychopharmacological research on nicotine and tobacco was important in the rationale and development of the treaty. The public health relevance of psychopharmacology research continues to grow with the realization of the potential of nicotine and related drugs to treat or prevent a diverse range of disorders (e.g., Alzheimer's disease, attention deficit hyperactivity disorder, and pain). Although comprehensive review of the research and implications is beyond the scope of this article, the more modest goal of providing insight into the theoretical, clinical, and policy importance of key psychopharmacology research laboratories over the past few decades is attempted.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, 3rd edn. American Psychiatric Association, Washington, DCGoogle Scholar
  2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn. Revised. American Psychiatric Association, Washington, DCGoogle Scholar
  3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  4. Balfour DJ, Fagerstrom KO (1996) Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72:51–81PubMedCrossRefGoogle Scholar
  5. Balster RL (1983) Comments on abuse liability of Nicorette. FDA Drug Abuse Advisory Committee, Rockville, MDGoogle Scholar
  6. Balster RL, Bigelow GE (2003) Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70:S13–S40PubMedCrossRefGoogle Scholar
  7. Barry H, III (2005) Censorship by a tobacco company. Psychopharmacology 184:273PubMedCrossRefGoogle Scholar
  8. Benowitz NL, Henningfield JE (1994) Establishing a nicotine threshold for addiction. The implications for tobacco regulation. New Engl J Med 331:123–125Google Scholar
  9. Benowitz NL, Hall SM, Herning RI, Jacob P, III, Jones RT, Osman AL (1983) Smokers of low-yield cigarettes do not consume less nicotine. New Engl J Med 309:139–142PubMedCrossRefGoogle Scholar
  10. Borland R, Davey C (2004) Impact of smoke-free bans and restrictions. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 707–732Google Scholar
  11. Browne CL (1990) The design of cigarettes. Hoechst Celenese Corporation, Charlotte, North CarolinaGoogle Scholar
  12. Butschky MF, Bailey D, Henningfield JE, Pickworth WB (1995) Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav 50:91–96PubMedCrossRefGoogle Scholar
  13. Collins AC, Romm E, Wehner JM (1988) Nicotine tolerance: an analysis of the time course of its development and loss in the rat. Psychopharmacology 96:7–14PubMedCrossRefGoogle Scholar
  14. Corrigall WA (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1:11–20PubMedCrossRefGoogle Scholar
  15. Daynard RA (2004) Roles of tobacco litigation and societal change. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 695–705Google Scholar
  16. De Beyer J, Brigden LW (2003) Tobacco control policies: strategies, success, and setbacks. World Bank, Research for International Tobacco Control, Ottawa, CAGoogle Scholar
  17. DeNoble VJ, Mele PC (2005) Intravenous nicotine self-administration in rats: effects of mecamy-lamine, hexamethonium and naloxone. Psychopharmacology 184:266–272CrossRefGoogle Scholar
  18. Djordjevic MV, Hoffman D, Glynn T, Connolly GN (1995) Assessment of nicotine, moisture, and pH. Tob Control 4(1):62–66CrossRefGoogle Scholar
  19. Domino EF (1999) Pharmacological significance of nicotine. In: Gorrod JW, Jacob P (eds) Analytical determination of nicotine and related compounds and their metabolites. Elsevier, Amsterdam, pp 1–11CrossRefGoogle Scholar
  20. Drobes D, Klein LC (2004) Research on nicotine and tobacco: a decade of progress. Nicotine Tob Res 6:695–741PubMedCrossRefGoogle Scholar
  21. Fant RV, Henningfield JE, Nelson RA, Pickworth WB (1999) Pharmacokinetics and pharmaco-dynamics of moist snuff in humans. Tob Control 8:387–392PubMedCrossRefGoogle Scholar
  22. Ferno O (1973) A substitute for tobacco smoking. Psychopharmacologia 31:201–204PubMedCrossRefGoogle Scholar
  23. Ferno O (1977) The development of a chewing gum containing nicotine and some comments on the role played by nicotine in the smoking habit. In: Steinfeld J, Griffiths W, Ball K, Taylor RM (eds) Proceedings of the third world conference on smoking and health. US Department of Health, Education, and Welfare, Washington, DC, pp 569–573Google Scholar
  24. Finnegan JK, Larson PS, Haag HB (1945) The role of nicotine in the cigarette habit. Science 102:94–96PubMedCrossRefGoogle Scholar
  25. Food and Drug Administration (1995) Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Fed Regist 60:41314–41792Google Scholar
  26. Food and Drug Administration (1996) Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Fed Regist 61:44396–45318Google Scholar
  27. Goldberg KB (2004) NCI programs: NCI to fund lab testing of “reduced harm” tobacco. Cancer Lett 30:3–5Google Scholar
  28. Goldberg SR, Spealman RD, Goldberg DM (1981) Persistent behavior at high rate maintained by intravenous self-administration of nicotine. Science 214:573–575PubMedCrossRefGoogle Scholar
  29. Goldberg SR, Spealman RD, Risner ME, Henningfield JE (1983) Control of behavior by intravenous nicotine injections in laboratory animals. Pharmacol Biochem Behav 19:1011–1020PubMedCrossRefGoogle Scholar
  30. Gray N (2004) Global tobacco control policy. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 659–668Google Scholar
  31. Griffiths RR, Bigelow GE, Henningfield JE (1980) Similarities in animal and human drug-taking behavior. In: Mello NK (ed) Advances in substance abuse. JAI, Greenwich, CT, pp 1–90Google Scholar
  32. Griffiths RR, Henningfield JE (1982) Experimental analysis of human cigarette smoking behavior. Fed Proc 41:234–240PubMedGoogle Scholar
  33. Gritz ER (1980) Smoking behavior and tobacco use. In: Mello NK (ed) Advances in substance abuse. JAI, Greenwich, CT, pp 91–158Google Scholar
  34. Grunberg NE, Popp KA, Bowen DJ, Nespor SM, Winders SE, Eury SE (1988) Effects of chronic nicotine administration on insulin, glucose, epinephrine, and norepinephrine. Life Sci 42: 161–170PubMedCrossRefGoogle Scholar
  35. Hall SM, Tunstall CD, Ginsberg D, Benowitz NL, Jones RT (1987) Nicotine gum and behavioral treatment: a placebo controlled trial. J Consult Clin Psychol 55:603–605PubMedCrossRefGoogle Scholar
  36. Harris LS (1988) Problems of drug dependence 1987. Proceedings of the 49th annual scientific meeting of the Committee on Problems of Drug Dependence, Philadelphia, June 1987. NIDA Research Monograph no. 81. US Department of Health and Human Services, Rockville, MDGoogle Scholar
  37. Hatsukami DK, Hughes JR, Pickens RW, Svikis D (1984) Tobacco withdrawal symptoms: an experimental analysis. Psychopharmacology 84:231–236PubMedCrossRefGoogle Scholar
  38. Henningfield JE (1984) Behavioral pharmacology of cigarette smoking. In: Thompson T, Dews PB, Barrett JE (eds) Advances in behavioral pharmacology, vol 4. Academic, New York, pp 131–210Google Scholar
  39. Henningfield JE (1995) Statement of David Kessler, Commissioner of Food and Drugs, Food and Drug Administration, Accompanied by Jack E. Henningfield, Chief, Clinical Pharmacology Branch, National Institute on Drug Abuse. Hearings Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Third Congress, Second Session. U.S. Government Printing Office, Washington, DC, pp 36–37Google Scholar
  40. Henningfield JE (2004) Written direct examination of Jack E. Henningfield, PhD. submitted by the United States pursuant to order #471Google Scholar
  41. Henningfield JE, Goldberg SR (1983) Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 19:989–992PubMedCrossRefGoogle Scholar
  42. Henningfield JE, Goldberg SR (1988) Progress in understanding the relationship between the pharmacological effects of nicotine and human tobacco dependence. Pharmacol Biochem Behav 30:217–220PubMedCrossRefGoogle Scholar
  43. Henningfield JE, Hartel CR (1999) Scientific basis for tobacco policy: nicotine research travails. In: Glantz MD, Hartel CR (eds) Drug abuse: origins and interventions. American Psychological Association, Washington, DC, pp 431–446CrossRefGoogle Scholar
  44. Henningfield JE, Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:743–750PubMedCrossRefGoogle Scholar
  45. Henningfield JE, Slade J (1998) Tobacco-dependence medications: public health and regulatory issues. Food Drug Law 53(suppl):75–114Google Scholar
  46. Henningfield JE, Woodson PP (1989) Dose-related actions of nicotine on behavior and physiology: Review and implications for replacement therapy for nicotine dependence. J Subst Abuse, 1:301–317Google Scholar
  47. Henningfield JE, Zeller M (2002) Could science-based regulation make tobacco products less addictive? Yale J Health Policy Law Ethics III:127–138Google Scholar
  48. Henningfield JE, Zeller M (2006) Nicotine psychopharmacology research contributions to United States and global tobacco regulation: A look back and a look forward. Psychopharmacology 184:286–291PubMedCrossRefGoogle Scholar
  49. Henningfield JE, Miyasato K, Jasinski DR (1983) Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav 19:887–890PubMedCrossRefGoogle Scholar
  50. Henningfield JE, Miyasato K, Jasinski DR (1985) Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234:1–12PubMedGoogle Scholar
  51. Henningfield JE, London ED, Jaffe JH (1987) Nicotine reward: studies of abuse liability and physical dependence potential. In: Engel J, Orleand L (eds) Brain reward systems and abuse. Raven, New York, pp 147–164Google Scholar
  52. Henningfield JE, Kozlowski LT, Benowitz NL (1994) A proposal to develop meaningful labeling for cigarettes. JAMA 272:312–314PubMedCrossRefGoogle Scholar
  53. Henningfield JE, Radzius A, Cone EJ (1995) Estimation of available nicotine content of six smokeless tobacco products. Tob Control 4(1):57–61CrossRefGoogle Scholar
  54. Henningfield JE, Keenan RM, Clarke PBS (1996) Nicotine. In: Schuster CR, Kuhar MJ (eds) Handbook of experimental pharmacology. Springer, Berlin, pp 271–214Google Scholar
  55. Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD (1998) Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control 7:281–293Google Scholar
  56. Henningfield JE, Benowitz NL, Connolly GN, Davis RM, Gray N, Myers ML, Zeller M (2004) Reducing tobacco addiction through tobacco product regulation. Tob Control 13:132–135PubMedCrossRefGoogle Scholar
  57. Henningfield JE, Stolerman IP, Miczek KA (2006) Nicotine psychopharmacology research: Advancing science, public health, and global policy. Psychopharmacology 184:263–265PubMedCrossRefGoogle Scholar
  58. Houtsmuller EJ, Fant RV, Eissenberg TE, Henningfield JE, Stitzer ML (2002) Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav 72: 559–568PubMedCrossRefGoogle Scholar
  59. Houtsmuller EJ, Henningfield JE, Stitzer ML (2003) Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology 167:20–27PubMedGoogle Scholar
  60. Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatr 43:289–294PubMedGoogle Scholar
  61. Hurt RD, Robertson CR (1998) Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota tobacco trial. JAMA 280:1173–1181PubMedCrossRefGoogle Scholar
  62. Jaffe JH, Jarvik ME (1978) Tobacco use and tobacco disorder. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven, New York, pp 1665–1676Google Scholar
  63. Jarvik ME (1977) Biological factors underlying the smoking habit. In: Jarvik ME, Cullen JW, Gritz ER, Vogt TM, West LJ (eds) Research on smoking behavior. NIDA Research Monograph 17. US Department of Health, Education, and Welfare, Washington, DC, pp 122–148Google Scholar
  64. Jarvik ME, Cullen JW, Gritz ER, Vogt TM, West LJ (1977) Research on smoking behavior. NIDA Research Monograph 17, DHEW publication no. (ADM) 78–581. US Department of Health, Education and Welfare, Washington, DCGoogle Scholar
  65. Jha P, Ross H, Corrao MA, Chaloupka FJ (2004) Effective interventions to reduce smoking. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 733–748Google Scholar
  66. Johnston LM, Glasg MB (1941) Tobacco smoking and nicotine. Lancet 1:867Google Scholar
  67. Kessler DA (1995) Statement of David Kessler, Commissioner of Food and Drugs, Food and Drug Administration, Accompanied by Jack E. Henningfield, Chief, Clinical Pharmacology Branch, National Institute on Drug Abuse. Hearings Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Third Congress, Second Session. US Government Printing Office, Washington, DC, pp 28–43Google Scholar
  68. Kessler DA (2001) A question of intent: a great American battle with a deadly industry. Public Affairs, New YorkGoogle Scholar
  69. Koop CE (2003) Tobacco addiction: accomplishments and challenges in science, health, and policy. Nicotine Tob Res 5:613–619PubMedCrossRefGoogle Scholar
  70. Koop EC (2004) Tobacco: the public health disaster of the twentieth century. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp v–xviiGoogle Scholar
  71. Krasnegor NA (1979a) Cigarette smoking as a dependence process. NIDA Research Monograph 23. Public Health Service, US Department of Health, Education, and Welfare, Washington, DCGoogle Scholar
  72. Krasnegor NA (1979b) The behavioral aspects of smoking. NIDA Research Monograph 26. Public Health Service, US Department of Health, Education, and Welfare, Washington, DCGoogle Scholar
  73. Langley JN (1905) On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol 33:374–413PubMedGoogle Scholar
  74. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, Corrigall WA (2007) Translational research in medication development for nicotine dependence. Nat Rev Drug Disc 6:746–762CrossRefGoogle Scholar
  75. Lewin L (1998) Phantastica: a classic survey on the use and abuse of mind-altering plants. Park Street, Rochester, VTGoogle Scholar
  76. London ED, Connolly RJ, Szikszay M, Wamsley JK, Dam M (1988) Effects of nicotine on local cerebral glucose utilization in the rat. J Neurosci 8:3920–3928PubMedGoogle Scholar
  77. Markou A (2008) Neurobiology of nicotine dependence. Phil Trans R Soc B 363:3159–3168PubMedCrossRefGoogle Scholar
  78. Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC (1986) Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol Pharmacol 30:427–436PubMedGoogle Scholar
  79. Mullins B (2004) How Philip Morris, tobacco foes tied the knot. Roll Call, 5 Oct 2004. Available at: http://www.rollcall.com/issues/50_39/news/7035-1.html. Last accessed 30 Oct 2008
  80. Myers ML (2002) Could product regulation result in less hazardous tobacco products? Yale J Health Policy Law Ethics III: 139–147Google Scholar
  81. National Cancer Institute (1996) The FTC cigarette test method for determining tar, nicotine, and carbon monoxide yields of U.S. Cigarettes. Report of the NCI Expert Committee. Smoking and Tobacco Control Monograph 7. National Institutes of Health, National Cancer Institute, Bethesda, MDGoogle Scholar
  82. National Cancer Institute (2001) Risks associated with smoking cigarettes with low machine-measured yields. Smoking and Tobacco Control Monograph 13. National Institutes of Health, National Cancer Institute, Bethesda, MDGoogle Scholar
  83. National Institute on Drug Abuse (NIDA) (1984) Drug abuse and drug abuse research. Public Health Service, US Department of Health and Human Services, National Institute on Drug Abuse, Rockville, MDGoogle Scholar
  84. National Institute on Drug Abuse (NIDA) (1987) The Second Triennial Report to Congress From the Secretary, US Department of Health and Human Services. National Institute on Drug Abuse, Rockville, MDGoogle Scholar
  85. Overton DA (1969) Control of T-maze choice by nicotinic, antinicotinic, and antimuscarinic drugs. Proceedings of the 77th Annual American Psychological Association Convention. 4:869–870Google Scholar
  86. Palmatier MI, Evans-Martin FF, Hoffman A, Caggiula AR, Chaudhri N, Donny EC, Liu X, Booth S, Gharib M, Craven L, Alan F, Sved AF (2006) Dissociating the primary reinforcing and reinforcement-enhancing effects of nicotine using a rat self-administration paradigm with concurrently available drug and environmental reinforcers. Psychopharmacology 184:391–400PubMedCrossRefGoogle Scholar
  87. Perkins KA, DiMarco A, Grobe JE, Scierka A, Stiller RL (1994a) Nicotine discrimination in male and female smokers. Psychopharmacology 116:407–413CrossRefGoogle Scholar
  88. Perkins KA, Sexton JE, Reynolds WA, Grobe JE, Fonte C, Stiller RL (1994b) Comparison of acute subjective and heart rate effects of nicotine intake via tobacco smoking versus nasal spray. Pharmacol Biochem Behav 47:295–299CrossRefGoogle Scholar
  89. Pertschuk M (2001) Smoke in their eyes: lessons in movement leadership from the tobacco wars. Vanderbilt University Press, Nashville, TNGoogle Scholar
  90. Pickworth WB, Bunker EB, Henningfield JE (1994) Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology 115:9–14PubMedCrossRefGoogle Scholar
  91. Pinney JM (1979) Preface. In: Krasnegor NA (ed) Cigarette smoking as a dependence process. NIDA Research Monograph 23. Public Health Service, Department of Health Education and Welfare, Washington, DC, pp vii–viiiGoogle Scholar
  92. Pomerleau OF, Hughes JR (2005) With a little help from its friends: a brief history of the Society for Research on Nicotine and Tobacco. Nicotine Tob Res 6(3):391–395CrossRefGoogle Scholar
  93. Miczek KA, Stolerman IP, Henningfield JE (eds) (2006) Special issue on nicotine. Psychopharma-cology 184(3–4):263–652Google Scholar
  94. Roemer R (2004) A brief history of legislation to control the tobacco epidemic. In: Boyle P, Gray N, Henningfield JE, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 677–694Google Scholar
  95. Rose JE, Jarvik ME, Rose KD (1984) Transdermal administration of nicotine. Drug Alcohol Depend 13:209–213PubMedCrossRefGoogle Scholar
  96. Rosecrans JA, Kallman MJ, Glennon R (1978) The nicotine cue: an overview. In: Colpaert FC, Rosecrans JA (eds) Stimulus properties of drugs: ten years of progress. Elsevier/North-Holland Biomedical, Amsterdam, pp 69–81Google Scholar
  97. Royal College of Physicians. (2000) Nicotine addiction in Britain: a report of the tobacco advisory group of the Royal College of Physicians. Royal College of Physicians of London, LondonGoogle Scholar
  98. Russell MAH (1971) Cigarette smoking: natural history of a dependence disorder. Br J Psychol 44:1–16Google Scholar
  99. Russell MAH (1979) Tobacco dependence: is nicotine rewarding or aversive? In: Krasnegor NA (ed) Cigarette smoking as a dependence process. NIDA Research Monograph 23. Public Health Service, US Department of Health Education and Welfare, Washington, DC, pp 100–122Google Scholar
  100. Russell MAH (1988) Nicotine replacement: the role of blood nicotine levels, their rate of change, and nicotine tolerance. In: Pomerleau OF, Pomerleau CS, Fagerstrom KO, Henningfield JE, Hughes JR (eds) Nicotine replacement: a critical evaluation. Alan R. Liss, New York, pp 63–94Google Scholar
  101. Schneider NG, Jarvik ME, Forsythe AB (1984) Nicotine vs. placebo gum in the alleviation of withdrawal during smoking cessation. Addict Behav 9:149–156PubMedCrossRefGoogle Scholar
  102. Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML (1997) Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 130:352–361PubMedCrossRefGoogle Scholar
  103. Schuster CR, Henningfield J (2003) Conference on abuse liability assessment of CNS drugs. Drug Alcohol Depend 70:S1–S4PubMedCrossRefGoogle Scholar
  104. Schwartz JL (1987) Review and evaluation of smoking cessation methods: the United States and Canada, 1979–1985. NIH Publication no. 87–2940. Public Health Service, National Institutes of Health, US Department of Health and Human Services, Rockville, MDGoogle Scholar
  105. Schwartz RD, Kellar KJ (1983) Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 220:214–216PubMedCrossRefGoogle Scholar
  106. Shiffman SM, Jarvik ME (1976) Smoking withdrawal symptoms in two weeks of abstinence. Psy-chopharmacology 50:35–39Google Scholar
  107. Shram MJ, Li Z, Lê AD (2008) Age differences in the spontaneous acquisition of nicotine self-administration in male Wistar and Long–Evans rats. Psychopharmacology, 197:45–58CrossRefGoogle Scholar
  108. Slade J, Henningfield JE (1998) Tobacco product regulation: context and issues. Food Drug Law J 53(suppl):43–74PubMedGoogle Scholar
  109. Slade J, Bero LA, Hanauer P, Barnes DE, Glantz SA (1995) Nicotine and addiction. The Brown and Williamson documents. JAMA 274:225–233PubMedCrossRefGoogle Scholar
  110. Spillane J, McAllister WB (2003) Keeping the lid on: a century of drug regulation and control. Drug Alcohol Depend 70:S5–S12PubMedCrossRefGoogle Scholar
  111. Stitzer ML, De Wit H (1998) Abuse liability of nicotine. In: Benowitz NL (ed) Nicotine safety and toxicity. Oxford University Press, Oxford, pp 119–131Google Scholar
  112. Stolerman IP, Goldfarb T, Fink R, Jarvik ME (1973) Influencing cigarette smoking with nicotine antagonists. Psychopharmacology 28:247–259CrossRefGoogle Scholar
  113. Stratton K, Shetty P, Wallace R, Bondurant S (eds) (2001) Clearing the smoke: assessing the science base for tobacco harm. National Academy, Washington, DCGoogle Scholar
  114. Talhout R, Opperhuizen A, vanAmsterdam GC (2007) Role of acetaldehyde in tobacco smoke addiction. Eur Neuropsychopharmacol 17:627–636PubMedCrossRefGoogle Scholar
  115. US Department of Health and Human Services (USDHHS) (1984) Why people smoke cigarettes. (PHS) 83–50195. Public Health Service, US Department of Health and Human Services, Rockville, MD, pp. 1–5Google Scholar
  116. US Department of Health and Human Services (USDHHS) (1988) The health consequences of smoking: nicotine addiction. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Center for Health Promotion and Education, Office on Smoking and Health, Rockville, MDGoogle Scholar
  117. US Department of Health, Education, and Welfare (USDHHS) (1979) Smoking and health, a report of the Surgeon General. US Department of Health, Education, and Welfare, Washington, DCGoogle Scholar
  118. Vagg R, Chapman S (2005) Nicotine analogues: a review of tobacco industry research interests. Addiction 100:701–712PubMedCrossRefGoogle Scholar
  119. Warner KE, Slade J, Sweanor DT (1997) The emerging market for long-term nicotine maintenance. JAMA 278:1087–1092PubMedCrossRefGoogle Scholar
  120. Warner KE, Peck CC, Woosley RL, Henningfield JE, Slade J (1998) Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease: preface. Food Drug Law J 53(suppl):1–8PubMedGoogle Scholar
  121. Wayne GF, Connolly GN, Henningfield JE (2004) Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence. Nicotine Tob Res 6:927–940PubMedCrossRefGoogle Scholar
  122. Wayne GF, Connolly GN, Henningfield JE (2006) Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents. Tob Control 15:189–198CrossRefGoogle Scholar
  123. Wayne FE, Connolly GN, Henningfield JE, Farone WA (2008) Tobacco industry research and efforts to manipulate smoke particle size: implications for product regulation. Nicotine Tob Res 10:613–625PubMedCrossRefGoogle Scholar
  124. World Bank (1999) Curbing the epidemic: governments and the economics of tobacco control. The International Bank for Reconstruction and Development, The World Bank, Washington, DCGoogle Scholar
  125. World Health Organization (1992) The ICD-10 classification of mental behavioural disorders. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  126. World Health Organization (1999) Conclusions to the conference on the regulation of tobacco products. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  127. World Health Organization (2001) Advancing knowledge on regulating tobacco products. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  128. World Health Organization Study Group on Tobacco Product Regulation (2004) Recommendation: guiding principles for the development of tobacco product research and testing capacity and proposed protocols for the initiation of tobacco product testing. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  129. World Health Organization (2004) The scientific basis of tobacco product regulation, Report of a WHO Study Group, WHO Technical Series 945, Geneva, SwitzerlandGoogle Scholar
  130. World Health Organization (2007) Tobacco free initiative. The scientific basis of tobacco product regulation. Available online at: http://www.who.int/tobacco/global_interaction/tobreg/tsr/en/ index.html

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Jack E. Henningfield
    • Mitch Zeller
      • 1
    1. 1.Pinney AssociatesBethesdaUSA

    Personalised recommendations